Korro Bio Q2 net loss $21.8M; cash $187.8M; KRRO-110 FIH filing on track

Korro Bio, Inc.

2024-Q2 EPS reported -$4.87

Net loss of $21.8M for Q2 2024, up from $17.6M in Q2 2023, driven by higher R&D and G&A costs.
Cash, equivalents & marketable securities total $187.8M as of June 30, 2024; runway into H2 2026.
Regulatory filing for KRRO-110 first-in-human trial in AATD expected in H2 2024.
Preclinical data showed >70% M-AAT protein in circulation with ~60% sustained editing efficiency.
Completed $70M private placement in April 2024 to support pipeline development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.